Moberg Pharma Past Earnings Performance
Past criteria checks 0/6
Moberg Pharma's earnings have been declining at an average annual rate of -59%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been declining at an average rate of 15.8% per year.
Key information
-58.98%
Earnings growth rate
-28.90%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.53% |
| Revenue growth rate | -15.84% |
| Return on equity | -3.87% |
| Net Margin | -176.32% |
| Next Earnings Update | 13 Aug 2026 |
Recent past performance updates
Recent updates
Narrative Update • Jun 24
MOB: Expanded Licensing Network Will Drive Future Upside Potential
Analysts have kept their fair value estimate for Moberg Pharma steady at SEK 14.0 per share, reflecting unchanged assumptions on discount rate, revenue growth, profit margin and future P/E despite the updated price target data. What’s in the News for Moberg Pharma The first European countries have approved the rebranding of MOB-015 (Terclara) to Karo Healthcare's brand, with commercial production and launch activities planned ahead of the high season, source: company key developments.Analysis Article • Jun 18
We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Narrative Update • Jun 02
MOB: Dual Terbinafine Supply And Expanded Licensing Will Support Future Re Rating Potential
Analysts have adjusted their price target on Moberg Pharma to SEK14.00 from SEK13, reflecting updated assumptions around revenue growth, profit margins, discount rate and future P/E. These changes collectively reshape their view of the stock’s risk and reward profile.Narrative Update • Apr 21
MOB: Dual Terbinafine Suppliers And Broader Mandate Will Support Future Re Rating Potential
Analysts now hold the fair value estimate for Moberg Pharma steady at SEK 13.0, reflecting unchanged assumptions on discount rate, revenue growth, profit margin and future P/E, and indicating that the recent review has not altered their SEK-based price target framework. What's in the News Moberg Pharma plans to propose an amendment to its articles of association at the AGM scheduled for 21 May 2026.Narrative Update • Apr 06
MOB: Dual Terbinafine Sourcing Will Support Future Re Rating Potential
Analysts have reaffirmed their price target for Moberg Pharma at SEK 13.0 per share, citing unchanged views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Regulators have approved an additional supplier of terbinafine for MOB-015, Moberg Pharma's drug for nail fungus, after a process that started in April 2024 (Key Developments).Narrative Update • Mar 23
MOB: Dual Supplier Approval Will Support Future Re Rating Potential
Analysts have maintained their SEK fair value estimate for Moberg Pharma at SEK 13.0, with unchanged assumptions for the discount rate, revenue growth, profit margin and future P/E. This suggests their view on the company’s risk and earnings outlook remains essentially intact.Narrative Update • Mar 07
MOB: Stable Assumptions And Profitability Outlook Will Support Future Re Rating
Analysts have maintained their SEK 13.0 price target for Moberg Pharma, reflecting unchanged views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. Valuation Changes Fair Value: SEK 13.0 is unchanged, with only rounding differences between the previous SEK 13 and the current SEK 13.0 figure.Narrative Update • Feb 21
MOB: Higher Profitability Assumptions Will Support Re Rating Of Undervalued Shares
Analysts have adjusted their price target on Moberg Pharma to SEK 13.0. This reflects updated views on revenue growth, profit margin and a lower future P/E assumption. Valuation Changes Fair Value: SEK 13.0 is unchanged, indicating no revision to the overall price estimate.Narrative Update • Feb 05
MOB: Undervalued Shares Will Rely On Stable Assumptions To Re-Rate
Analysts have kept their price target for Moberg Pharma steady at SEK 13.00. This reflects unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E.Narrative Update • Jan 22
MOB: Europe Licensing Agreement Will Support Future Share Price Upside
Analysts have kept their price target for Moberg Pharma steady at SEK 13.0. This reflects unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E despite the latest review of their model inputs. What's in the News Karo Healthcare AB and Moberg Pharma AB have signed an exclusive licensing agreement for the commercialisation of MOB-015 in 19 European markets, covering a population of about 500 million people (Key Developments).Narrative Update • Jan 08
MOB: Europe Licensing Agreement Will Support Strong Future Share Price Upside
Analysts have maintained their price target on Moberg Pharma at SEK 13.0, with unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. This indicates their core view on the stock remains intact for now.Narrative Update • Dec 16
MOB: Exclusive European Licensing Deal Will Drive Strong Future Share Upside
Analysts have marginally adjusted their price target on Moberg Pharma, reiterating a fair value of SEK 13.0 per share as they maintain their assumptions for discount rate, revenue growth, profit margins, and future valuation multiples. What's in the News Karo Healthcare AB signs an exclusive licensing agreement with Moberg Pharma for the commercialisation of MOB-015 across 19 European markets, including all major EU countries and the United Kingdom, ensuring a coordinated launch under the Lamisil brand (Company announcement) The licensing deal grants Karo responsibility for marketing, distribution, and sales in 11 countries where MOB-015 is already approved but not yet launched, accelerating the product’s European rollout (Company announcement) MOB-015, a new topical terbinafine formulation, demonstrates mycological cure rates of 76 percent in registration studies, delivering efficacy on par with oral treatment and addressing historical challenges in penetrating the nail (Company announcement) The agreement provides Moberg Pharma with access to a total addressable population of about 500 million people in Europe, significantly expanding the commercial potential of MOB-015 (Company announcement) Valuation Changes Fair Value: Unchanged at SEK 13.0 per share, reflecting a stable outlook for Moberg Pharma’s intrinsic valuation.Narrative Update • Dec 02
MOB: Exclusive Licensing Deal Will Unlock Major European Market Launches
Analysts have maintained their price target for Moberg Pharma at SEK 13.00. This reflects continued confidence in the company's earnings outlook and growth potential.Narrative Update • Nov 18
MOB: Licensing Agreement Will Drive Expansion Across Europe This Year
Analysts have raised their price target for Moberg Pharma from SEK 11 to SEK 13. This change reflects updated forecasts that consider notable shifts in anticipated revenue growth, profitability, and market conditions.Analysis Article • Nov 07
We're Not Worried About Moberg Pharma's (STO:MOB) Cash Burn
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Analysis Article • May 16
Shareholders Will Probably Hold Off On Increasing Moberg Pharma AB (publ)'s (STO:MOB) CEO Compensation For The Time Being
Key Insights Moberg Pharma's Annual General Meeting to take place on 22nd of May Total pay for CEO Anna Ljung includes...
New Narrative • Apr 13
Norway Expansion And EU Approvals Will Strengthen Future Position
Expansion in Norway and obtaining EU approvals bolster revenue potential and support Moberg Pharma's European growth strategy.Analysis Article • Feb 12
Companies Like Moberg Pharma (STO:MOB) Can Afford To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • Sep 14
We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analysis Article • May 08
Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year
Key Insights Moberg Pharma to hold its Annual General Meeting on 14th of May Salary of kr1.99m is part of CEO Anna...Analysis Article • Nov 16
Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • Jan 17
Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Analysis Article • Dec 03
Read This Before Selling Moberg Pharma AB (publ) (STO:MOB) Shares
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Moberg Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 15 | -26 | 31 | 5 |
| 31 Dec 25 | 14 | -27 | 32 | 4 |
| 30 Sep 25 | 12 | -258 | 32 | 303 |
| 30 Jun 25 | 12 | -255 | 30 | 303 |
| 31 Mar 25 | 13 | -251 | 28 | 302 |
| 31 Dec 24 | 10 | -255 | 29 | 302 |
| 30 Sep 24 | 9 | -18 | 30 | 2 |
| 30 Jun 24 | 5 | -23 | 30 | 3 |
| 31 Mar 24 | 1 | -23 | 27 | 4 |
| 31 Dec 23 | 0 | -21 | 25 | 4 |
| 30 Sep 23 | 0 | -18 | 23 | 3 |
| 30 Jun 23 | 0 | -16 | 22 | 2 |
| 31 Mar 23 | 0 | -16 | 22 | 1 |
| 31 Dec 22 | 0 | -16 | 21 | 1 |
| 30 Sep 22 | 0 | -17 | 20 | 2 |
| 30 Jun 22 | 0 | -16 | 19 | 2 |
| 31 Mar 22 | 0 | -16 | 18 | 3 |
| 31 Dec 21 | 0 | -16 | 19 | 3 |
| 30 Sep 21 | 34 | 8 | 21 | 5 |
| 30 Jun 21 | 34 | 7 | 21 | 6 |
| 31 Mar 21 | 34 | 5 | 22 | 6 |
| 31 Dec 20 | 34 | 7 | 22 | 6 |
| 30 Jun 20 | 50 | 20 | 24 | 7 |
| 30 Jun 19 | 31 | -8 | 31 | 13 |
| 31 Mar 19 | 455 | 31 | 269 | 18 |
| 31 Dec 18 | 5 | -28 | 26 | 13 |
| 30 Sep 18 | 341 | 9 | 217 | 16 |
| 30 Jun 18 | 340 | 19 | 210 | 15 |
| 31 Mar 18 | 334 | 6 | 206 | 14 |
| 31 Dec 17 | 439 | 11 | 261 | 14 |
| 30 Sep 17 | 438 | -1 | 268 | 15 |
| 30 Jun 17 | 434 | 0 | 253 | 15 |
| 31 Mar 17 | 369 | 35 | 218 | 13 |
| 31 Dec 16 | 334 | 33 | 201 | 12 |
| 30 Sep 16 | 299 | 36 | 181 | 15 |
| 30 Jun 16 | 261 | 32 | 168 | 15 |
| 31 Mar 16 | 282 | 9 | 165 | 19 |
| 31 Dec 15 | 286 | 26 | 159 | 23 |
| 30 Sep 15 | 276 | 25 | 158 | 22 |
Quality Earnings: MOB is currently unprofitable.
Growing Profit Margin: MOB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MOB is unprofitable, and losses have increased over the past 5 years at a rate of 59% per year.
Accelerating Growth: Unable to compare MOB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MOB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.1%).
Return on Equity
High ROE: MOB has a negative Return on Equity (-3.87%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/03 05:06 |
| End of Day Share Price | 2026/07/03 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Moberg Pharma AB (publ) is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bjorn Rydell | ABG Sundal Collier Sponsored |
| Klas Pyk | Nordea Markets |
| Mats Hyttinge | Redeye |